MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
+0.040
+2.35%
Pre Market: 1.790 +0.05 +2.87% 09:24 04/23 EDT
OPEN
1.744
PREV CLOSE
1.700
HIGH
1.800
LOW
1.670
VOLUME
48.99K
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
0.8100
MARKET CAP
210.23M
P/E (TTM)
-0.9628
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Novan, Qualtrics International, BioNano Genomics, XL Fleet, or Atossa Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, XM, BNGO, XL, and ATOS.
PR Newswire - PRF · 23h ago
Atossa Therapeutics Files for Potential Sale of 13 Million Shares by Selling Stockholders
MT Newswires · 1d ago
BRIEF-Atossa Therapeutics Inc Files For Shelf Of Up To 13 Million Shares Of Common Stock By Selling Stockholders
reuters.com · 1d ago
Atossa Therapeutics says ovarian cancer patient begins treatment with oral endoxifen
Atossa Therapeutics (ATOS) announces that an ovarian cancer patient has begun treatment with the company's proprietary oral Endoxifen.The FDA previously issued a "Safe to Proceed" letter under their expanded access
Seekingalpha · 04/08 13:37
BRIEF-Atossa Therapeutics Announces Ovarian Cancer Patient Has Begun Treatment With Oral Endoxifen
reuters.com · 04/08 13:33
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious dise...
GlobeNewswire · 04/08 13:30
Estrogen Receptor Beta Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as Estrogen Receptor Beta Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 04/08 10:11
Atossa Therapeutics EPS misses by $0.76
Atossa Therapeutics (ATOS): FY GAAP EPS of -$1.97 misses by $0.76.Cash, cash equivalents and restricted cash of $39.7M.Press Release
Seekingalpha · 03/31 14:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATOS stock price target is 6.38 with a high estimate of 7.75 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 23
Institutional Holdings: 1.57M
% Owned: 1.30%
Shares Outstanding: 120.82M
TypeInstitutionsShares
Increased
6
803.44K
New
3
276.60K
Decreased
3
133.83K
Sold Out
8
103.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
No Data
About ATOS
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.